155 related articles for article (PubMed ID: 10836705)
1. Tc-99m sestamibi and In-111 DTPA octreotide uptake in breast carcinoma with neurendocrine differentiation.
Rubini G; D'Eredità G
Clin Nucl Med; 2000 Jun; 25(6):482-3. PubMed ID: 10836705
[TBL] [Abstract][Full Text] [Related]
2. [Complementary scintigraphic examinations (99mTc-MDP, 99mTc-MIBI and Octreoscan) in breast neoplasm assessment].
Stefănescu C; Chossiere L; Rusu V; Meignan M
Rev Med Chir Soc Med Nat Iasi; 1996; 100(3-4):165-8. PubMed ID: 9455458
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine carcinomas of the lung and role of 111In-DTPA-octreotide scintigraphy: preliminary results.
Oliaro A; Filosso PL; Bello M; Casadio C; Muni A; Greco B; Bertuccio G; Bisi G; Maggi G
J Cardiovasc Surg (Torino); 1996 Dec; 37(6):653-6. PubMed ID: 9016988
[TBL] [Abstract][Full Text] [Related]
4. Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma.
Kurtaran A; Scheuba C; Kaserer K; Schima W; Czerny C; Angelberger P; Niederle B; Virgolini I
J Nucl Med; 1998 Nov; 39(11):1907-9. PubMed ID: 9829581
[TBL] [Abstract][Full Text] [Related]
5. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptors and breast cancer.
van Eijck CH; Kwekkeboom DJ; Krenning EP
Q J Nucl Med; 1998 Mar; 42(1):18-25. PubMed ID: 9646641
[TBL] [Abstract][Full Text] [Related]
7. [Preliminary results on the use of scintigraphy with radiolabelled octreotide as diagnostic method in neuroendocrine and nonendocrine neoplasms of the lung].
Oliaro A; Filosso PL; Bellò M; Casadio C; Muni A; Angusti T; Masaneo I; Bisi G; Maggi G
Minerva Chir; 1997 Nov; 52(11):1335-8. PubMed ID: 9489331
[TBL] [Abstract][Full Text] [Related]
8. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
[TBL] [Abstract][Full Text] [Related]
9. Comparison of indium-111 octreotide and thallium-201 scintigraphy in patients mammographically suspected of having breast cancer: preliminary results.
Vural G; Unlü M; Atasever T; Ozur I; Ozdemir A; Gökçora N
Eur J Nucl Med; 1997 Mar; 24(3):312-5. PubMed ID: 9143470
[TBL] [Abstract][Full Text] [Related]
10. The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR.
Wang F; Wang Z; Wu J; Qu W; Yao W; Zhao J; Liu Z
Nucl Med Biol; 2008 Aug; 35(6):665-71. PubMed ID: 18678351
[TBL] [Abstract][Full Text] [Related]
11. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy.
Lastoria S; Vergara E; Palmieri G; Acampa W; Varrella P; Caracò C; Bianco RA; Muto P; Salvatore M
J Nucl Med; 1998 Apr; 39(4):634-9. PubMed ID: 9544670
[TBL] [Abstract][Full Text] [Related]
12. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
[TBL] [Abstract][Full Text] [Related]
13. Tc-99m tetrofosmin in breast carcinoma and axillary lymph node metastases: a comparative study with Tc-99m MIBI.
Akçay MN; Akin Y; Karabağ B; Ozcan O; Oren D
Clin Nucl Med; 1997 Dec; 22(12):832-4. PubMed ID: 9408644
[TBL] [Abstract][Full Text] [Related]
14. [111-indium DTPA octreotide scintigraphy in colorectal liver metastases].
Seifert JK; Görges R; Bockisch A; Junginger T
Langenbecks Arch Chir; 1997; 382(6):332-6. PubMed ID: 9498205
[TBL] [Abstract][Full Text] [Related]
15. In-111 DTPA-D-Phe1-octreotide SPECT in a rare case of anorectal small-cell undifferentiated neuroendocrine carcinoma.
Imperiale A; Blondet C; Choquet P; Constantinesco A
Clin Nucl Med; 2006 Oct; 31(10):652-4. PubMed ID: 16985380
[No Abstract] [Full Text] [Related]
16. Tecnetium-99m as alternative to produce somatostatin-labeled derivatives: comparative biodistribution evaluation with 111In-DTPA-octreotide.
Melo IB; Ueda LT; Araujo EB; Muramoto E; Barboz MF; Mengatti J; Buchpiguel CA; Silva CP
Cell Mol Biol (Noisy-le-grand); 2010 May; 56(2):31-6. PubMed ID: 20525456
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
18. Current imaging and possible therapeutic management of glucagonoma tumors: a case report.
Johnson DS; Coel MN; Bornemann M
Clin Nucl Med; 2000 Feb; 25(2):120-2. PubMed ID: 10656647
[TBL] [Abstract][Full Text] [Related]
19. (99M)Technetium-sestamibi scintimammography in non-palpable breast lesions found on screening X-ray mammography.
Gommans GM; van der Zant FM; van Dongen A; Boer RO; Teule GJ; de Waard JW
Eur J Surg Oncol; 2007 Feb; 33(1):23-7. PubMed ID: 17126524
[TBL] [Abstract][Full Text] [Related]
20. Occult breast cancer detection with technetium-99m-sestamibi: a case report.
Park YH; Ferrante J; Robinson RE; Arvay K
J Nucl Med Technol; 1999 Dec; 27(4):298-300. PubMed ID: 10646550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
